Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations

Until recently, estimation of β-amyloid plaque density as a key element for identifying Alzheimer's disease (AD) pathology as the cause of cognitive impairment was only possible at autopsy. Now with amyloid-positron emission tomography (amyloid-PET) neuroimaging, this AD hallmark can be detecte...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Dement (Amst)
Autors principals: Witte, Michael M., Foster, Norman L., Fleisher, Adam S., Williams, Monique M., Quaid, Kimberly, Wasserman, Michael, Hunt, Gail, Roberts, J. Scott, Rabinovici, Gil D., Levenson, James L., Hake, Ann Marie, Hunter, Craig A., Van Campen, Luann E., Pontecorvo, Michael J., Hochstetler, Helen M., Tabas, Linda B., Trzepacz, Paula T.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2015
Matèries:
Neuroimaging
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4878065/
https://ncbi.nlm.nih.gov/pubmed/27239516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dadm.2015.06.006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars